anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A medicinal preparation serving as an antidote and prophylactic against nicotinism is prepared by heating maltose or glucose with glacial acetic acid at 110 DEG  C. to 150 DEG  C. for 15 to 60 minutes, mixing the product so produced with terpin hydrate, previously treated with alkali and excess alkali neutralized, heating the mixture to 120-200 DEG  C. until the resultant product is dark brown, adding further maltose or glucose and reheating until the product is brownish black.  After cooling the mass may be powdered. A non-hygroscopic product is obtained by mixing with melted refined rosin, cooling and pulverizing the resultant product, which preferably contains 55 to 60% of refined rosin. The product may be incorporated into cigarettes or made into tablets.ALSO:Tobacco is impregnated with an alcoholic solution of a medecinal preparation serving as an antidote and prophylactic against nicotinism and dried. The medicinal preparation is prepared by heating maltose or glucose with glacial acetic acid at 110 DEG C. to 150 DEG C. for 15 to 60 minutes, mixing the product so produced with terpin hydrate, previously treated with alkali and excess alkali neutralised, heating the mixture to 120-200 DEG C. until the resultant product is dark-brown, adding further maltose or glucose and reheating until the product is brownish-black. After cooling the mass may be powdered.  A non-hygroscopic produce is obtained by mixing with melted refined resin, cooling and pulverising the resultant product which may contain 55 to 60% of resin.
Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions characterised by keratinocyte apoptosis, necroptosis and epidermal detachment. Several cytokines and cytotoxic proteins have been shown to be elevated in the blood and skin of SJS/TEN sufferers and biologics such as intravenous immune globulin and tumour necrosis factor (TNF)-alpha inhibitors have demonstrated good therapeutic potential. The exact pathogenic model of SJS/TEN however remains elusive. This systematic review aimed to evaluate the case-control studies of cytokines and cytotoxic proteins in the blister fluid and skin of adults with Stevens Johnson syndrome and/or toxic epidermal necrolysis. This review was registered with INPLASY and conducted in accordance with the PRISMA reporting guidelines. Potential bias was assessed using the NIH criteria. Eleven articles describing results from 96 cases and 170 controls were included. Fas, Fas ligand, Interleukin (IL)-8 and B-cell lymphoma (Bcl)-2 were elevated in SJS/TEN blister fluid and skin tissue, compared with healthy controls. IL-2, IL-6, TNF-alpha, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon-gamma and matrix metalloproteinase-2 were elevated in SJS/TEN blister fluid compared with fluid sampled from lesional controls. Granulysin, IL-33, TGF-beta-1 and IL-13 were elevated in SJS/TEN skin tissue compared with lesional lichen planus tissue, as was IL-13, IFN-gamma, IL-2 and IL-5, when compared with erythema multiforme tissue. A wide array of cytokines and cytotoxic proteins are present at higher concentrations in the blister fluid and skin tissue of SJS/TEN patients compared with healthy and lesional controls. Our findings suggest that these proteins may be pathogenic, as well as possibly markers for diagnosis, disease severity and course. They may also prove to be useful therapeutic targets. More research is needed.
OBJECTIVES: To estimate C-reactive protein (CRP) levels in Saudi women with and without polycystic ovary syndrome (PCOS), and to investigate the associations between CRP and metabolic syndrome (MetS) components.
METHODS: We randomly recruited 200 women with and without PCOS, between 18 and 38 years, in this age-matched case-control study. Study subjects were allocated to 1 of 4 groups according to the presence or absence of MetS. Interviews were conducted with all participants, and anthropometric measurements and blood samples were obtained for subsequent analysis of biochemical variables.
RESULTS: Two-thirds of the study population and all study subjects had central obesity. Fasting insulin and homeostasis model assessment insulin resistance index were significantly higher in PCOS and MetS groups than all other groups (P < 0.05). CRP levels were significantly higher among women with PCOS than their age-matched controls, regardless of the presence of MetS (P < 0.05). Body mass index was the only independent predictor of serum high-sensitivity-CRP, accounting for 17% of the variability in circulating levels (β = 0.407; 95% CI 0.248-0.472, P < 0.0001).
CONCLUSIONS: Obesity and insulin resistance are important risk factors for MetS in PCOS. The presence of MetS in PCOS subjects aggravates the proinflammatory state reflected by CRP levels.
This study was designed as a randomized controlled clinical trial, the study population consisted of 20 patients with missing maxillary posterior teeth and residual bone height 5-7mm. The sample was selected conveniently according to a list of inclusion and exclusion criteria, the participants were allocated randomly into two equal groups. All patients had sinus lift using piezosurgery device with simultaneous implant placement. In group I, blood clot was the only filling material. In group II, moldable, self-hardening calcium phosphate was the filling material. Clinical and radiographic evaluations were done through 6 months postoperatively.
Colorectal cancer (CRC) screening is recommended by the United States Preventative Services Task Force for adults age 45-75. Patient navigation is an evidence-based strategy to increase screening rates among racial and ethnic minorities. While patient navigation is an evidence-based approach to improve screening, there is a gap in understanding the multi-level influences on implementation of such programs across primary care practices, particularly using a health-equity focused, stakeholder-centered approach. Guided by the Practical, Robust Implementation and Sustainability Model (PRISM) and core health and racial equity principles, the investigative team aims to increase reach of patient navigation and show effectiveness through improvement in the percentage of Black and Hispanic patients completing CRC screening. Investigators will also utilize longitudinal tracking of implementation strategies to better track implementation or intervention adaptations navigation delivery in order to inform future scale up. The research team will conduct a stepped-wedged, randomized trial to roll out patient navigation and patient and provider reminders across 15 clinics (3 clinics per step, 5 six-month steps). Implementation strategies will include assessing for readiness, audit and feedback, building a community coalition, engaging consumers, modifying referral tracking, and training and educating clinical stakeholders. Researchers will use the electronic health record data with consideration for the Observational Medical Outcomes Partnership (OMOP) Common Data Model, additional patient-reported data, and study tracking logs to measure reach, effectiveness, adoption, implementation, and will use qualitative measures and site observations to document contextual factors, including examination of discrimination in patient experiences and provider referral patterns that may influence intervention delivery or CRC screening completion.
PCT No. PCT/IT92/00106 Sec. 371 Date Apr. 21, 1993 Sec. 102(e) Date Apr. 21, 1993 PCT Filed Aug. 25, 1992 PCT Pub. No. WO93/04689 PCT Pub. Date Mar. 18, 1993Provided are active principles having an antitumoral activity, extracted from plants of the family Palma, the subfamily Phoenicoideae and the genus Phoenix, and pharmaceutical preparations containing at least one of the substances and compositions present in said extracts. In comparison with all the other antitumoral drugs known to date, these active principles show increased selectivity on neoplastic cells and a lower involvement of the normal cells. Also provided is a process for extraction and separation of the components of the extracts, and their use for the preparation of antineoplastic drugs and drugs for the treatment of other pathologies.
Ramucirumab 8 milligrams per kilogram (mg/kg) administered intravenously (IV) once every 2 weeks. Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance or withdrawal of consent.
FIELD: ophthalmology.SUBSTANCE: invention is intended to prevent or treat visual impairment. For the prevention or treatment of visual impairment, such as macular degeneration, glaucoma or diabetic retinopathy, a composition containing the active ingredients is used: (a) ursodeoxycholic acid (UDCA) selected from ursodeoxycholic acid, taurosodeoxycholic acid and glycoursodeoxycholic acid; (b) a water-soluble starch conversion product, wherein the pH of said composition is 6.5-8. The water-soluble starch conversion product is maltodextrin. The minimum mass ratio of ursodeoxycholic acid and maltodextrin is 1: 13-1: 25. The specified composition is prepared for intravitreal injection. A single dose of UDCA for intravitreal injection is 50-100 μl at a concentration of 0.1-1.5 mg / ml.EFFECT: use of the invention provides an excellent effect of preventing or treating visual impairment diseases such as macular degeneration, glaucoma and diabetic retinopathy.8 cl, 24 dwg, 9 tbl, 12 ex
Follow these instructions unless otherwise instructed by your dental professional:

  1. Adults and pediatric patients 6 years of age or older, apply a thin ribbon of PreviDent® 5000 Dry Mouth to a toothbrush. Brush thoroughly once daily for two minutes, preferably at bedtime, in place of your regular toothpaste.
  2. After use, adults expectorate. For best results, do not eat, drink, or rinse for 30 minutes. Pediatric patients, ages 6-16 years, expectorate after use and rinse mouth thoroughly.
PURPOSE:The titled factor, produced from human lymphocytic cells and useful for inhibiting transplantation rejection of transplanted patients or treating autoimmune disease, allergy, abnormal lymphocytosis and cancer. CONSTITUTION:A cell DNA synthesis inhibitory factor, separated and purified from a cultivation supernant of T cell hybridoma prepared by fusing human lymphotic cells or human pripheral blood lymphotic cells, e.g. T cell groups separated as human peripheral blood lymphocytes oor human lymphocytes, etc., with human leukemic cell strains, etc., and having the following properties; (i) Molecular weight; 45,000-70,000 (measured by gel filtration chromatography). (ii) Unadsorbed on immobilized concanavalin A-sepharose. (iii) Isoelectric point; 4.5-5.5. (iv) Eluted with FPLC-Mono Q anion exchange chromatography at 0.5-0.7M common salt concentration. (v) Physico-chemical properties shown in the table. The above-mentioned factor is capable of inhibiting cell DNA synthesis of a wide range beyond animal species, e.g. humans, rats, mice, etc.
AIMS: Evidence shows stereotactic ablative body radiotherapy (SABR) is used as a non-invasive ablative therapy in the treatment of multisite oligometastatic (OM) and oligoprogressive (OP) diseases originating from metastatic breast cancer. This study aims to report the treatment outcomes and to investigate what factors that are prognostic in terms of local control, progression-free survival (PFS) and overall survival (OS) in patients receiving SABR for extracranial OM and OP diseases originating from metastatic breast cancer.
MATERIALS AND METHODS: A retrospective review on treatment records of patients with OM and OP from metastatic breast cancer who underwent SABR at a single was carried out. SABR was performed with daily image-guided radiotherapy (IGRT) using a dedicated robotic SABR machine. Local control, PFS and OS were calculated using Kaplan-Meier statistics and the post-treatment toxicity data was scored following the CTCAE v4.0 protocol. Univariate and multivariate Cox regression tests were used in the subgroup analysis of prognostic factors on PFS and OS including patients' age, types of follow-up imaging (staging CT only vs whole-body MR/PET), metastases status (OM vs OP), primary breast cancer tumour grade, hormone receptors (ER/PR/HER2) status, change of systemic treatments at SABR, number of metastases, SABR treatment sites and doses.
RESULTS: 56 metastatic breast cancer patients (38 patients with OM and 18 patients with OP) were involved in this retrospective review. The median follow-up was 35.6 months (range 4.0-132.9 months). The estimated local control at 1 , 2 and 5 years were 90.9%, 88.7% and 88.7%, respectively. The estimated median PFS was 19.2 months (95%CI 10.3-28.1 months); the PFS at 1, 2 and 5 years were 63.3%, 44.4% and 33.2%. The estimated OS at 1, 2 and 5 years were 98.0%, 91.9% and 74.3%, respectively with the estimated median OS of 105.1 months (95%CI 51.5-158.7 months). The vast majority of patients tolerated the treatment well with the commonest acute side effects as grade 1 fatigue. There were no statistically significant factors found in OS regression analysis. The types of follow-up imaging, metastases status, oestrogen receptor status, and number of metastases for SABR were statistically significant factors (p < 0.05) in the multivariate Cox regression analysis on PFS.
CONCLUSION: There are limited studies published on the efficacy and post-treatment toxicities of metastatic breast cancer OM and OP SABR with adequate length of follow-up. This study confirmed that SABR was a safe, non-invasive treatment option for patients with extracranial OM and OP diseases originated from primary breast cancer in terms of the acceptable post-treatment toxicities.
PURPOSE:To produce a water with a specified molecular ordering by measuring chemical reaction rates of water samples after irradiating an electromagnetic wave to the water samples with variations in irradiation amounts and by irradiating that electromagnetic wave to water at an irradiation amount determined based on the aforementioned measurement. CONSTITUTION:An electromagnetic wave is irradiated to water and that in an aqueous solution and a hydrous substance with variations in irradiation amount, and chemical reaction rates of the irradiated water and that in the aqueous solution and the hydrous substance are measured. An irradiation amount of the electromagnetic wave to be irradiated is determined based on these measurements, and the electromagnetic wave is irradiated to water, an aqueous solution and a hydrous substance at this determined irradiation amount. It is possible, as a result, to produce the water with a specified molecular ordering, the aqueous solution and the hydrous substance containing that water. These water, aqueous solution and hydrous substance have a wide application range, because their functions of promoting, stopping and suppressing reactions can be altered freely. For example, it is possible to attempt a bleeding of normal cells by promoting cell divisions, a normalization of cultivation for vegetable growth, a retention of food freshness, a suppression of abnormal cells, etc.
Introduction: The menstrual cycle is an important indicator of health in female athletes. Female elite adolescent dancers are expected to control their weight while also training intensely, which can lead to menstrual disorders. This study aimed to investigate the relationship between body composition and menstrual status in female elite adolescent dancers. Methods: In total, 131 female elite adolescent dancers (age: 15.9 ± 1.5 years) were enrolled in this study. We measured the height, weight, and body fat percentage (BFP) for each participant and calculated their body mass index (BMI). We gathered information on individual menstruation patterns and the participants' menstrual cycles over the previous year using recall methods. We then compared the differences between dancers with menstrual cycle disorders and those without. Primary amenorrhea was defined as menarche occurring after the age of 15, while secondary amenorrhe was defined as experiencing fewer than 5 or no menstrual periods for at least 3 of the previous 12 months. We conducted a reliability test using the same questionnaire 2 weeks later. Statistical significance was defined as P < .05, and we calculated the effect sizes (d) and 95% confidence intervals (95% CI). Results: The average BMI and BFP were 22.6 ± 3.0% and 19.4 ± 2.2 kg/m2, respectively. Low BFP and low BMI were observed in 51 (38.6%) and 47 (35.6%) participants, respectively. Primary amenorrhea in 3 participants (2.3%) and 29 (22.1%) reported experiencing secondary amenorrhea; they had lower BFP than the dancers who did not experience amenorrhea (P = .041, 95% CI, -2.51 to -0.05). Conclusion: Female elite adolescent dancers in China may have lower BFP and menstrual problems. Given that lower BFP may contribute to the occurrence of menstruation disorders, it is essential to pay an attention to both BFP and the menstruation status in female elite adolescent dancers.
OBJECTIVE: Verifying the intervertebral stability of each intervertebral fusion procedure, including transforaminal, posterior, and lateral lumbar interbody fusion (TLIF, PLIF, and LLIF, respectively), and the ratio of stress on the rods and pedicle screws during initial fixation may help select a fixation procedure that reduces the risk of mechanical complications, including rod fracture and screw loosening. Thus, we aimed to assess whether these procedures could prevent mechanical complications.
METHODS: Using the finite element method (FEM), we designed 4 surgical models constructed from L2-5 as follows: posterior lumbar fusion (PLF), TLIF, PLIF, and LLIF models. Bilateral rods and each pedicle screw stress were tracked and calculated as Von Mises stress (VMS) for comparison among the PLF and other 3 interbody fusion models during flexion, extension, and side-bending movements.
RESULTS: The lowest rod VMS was LLIF, followed by PLIF, TLIF, and PLF in flexion and side bending movements. Compared with PLF, intervertebral fixation significantly reduced stress on the rods. No remarkable differences were observed in extension movements in each surgical procedure. A tendency for higher pedicle screw VMS was noted at the proximal and distal ends of the fixation ranges, including L2 and L5 screws for each procedure in all motions. Intervertebral fixation significantly reduced stress on the L2 and L5 screws, particularly in LLIF.
CONCLUSIONS: Stress on the rods and pedicle screws in the LLIF model was the lowest compared with that induced by other intervertebral fusion procedures. Therefore, LLIF may reduce mechanical complications occurrence, including rod fracture and screw loosening.
The invention relates to a method for building a spleen-deficiency chronic atrophic gastritis gastric precancerous lesions animal model. The method is based on the existing spleen-deficiency rat model and the existing chronic atrophic gastritis rat model and is used for building the animal model through united copy of free drinking of N-methyl-N '-nitro-N -nitrosoguanidine (MNNG) solution, irregular eating and purgation. The method comprises the following specific steps of: preparing 10mg/L MNNG storage solution by utilizing sterilized tap water, preparing 80 to 200 mug/mL MNNG solution in temporary use to substitute the drinking water to be drunk freely by the rats, and adopting the free drinking of MNNG as the beginning of the modeling; copying a spleen-deficiency syndrome through irregular eating and improved purgation way, feeding the rats on alternate days since the fifth week after the modeling, and utilizing qi-activating decoction for gavage in a dose of 1 to 3ml per rat every day in the seventh weak; and continuing the modeling for 12 weeks. The animal model built through the method is identical to or similar with the clinical syndrome and physical signs of middle-late lesions in chronic atrophic gastritis. After being verified in repeatedly modeling, the method has good repeatability and good stability. The built model is suitable for selecting traditional Chinese medicine for treating the chronic atrophic gastritis through a traditional Chinese medicine spleen treatment method.
PURPOSE: To obtain new 2,4-thiazolidinedione compds. useful as ingredients of drug compsns. effective in treating non-insulinogenic diabetes.  
     CONSTITUTION: The 2,4-thiazolidinedione compds. are compds. of formula I [where the broken line denotes the presence or absence of a double bond; and R is a group of formula II (where R 1  is H, a halogen, a 1-6C alkyl or a 6-6C alkoxy; and X is CH or N) or formula III (where Y is NH, O or S)], their isomers, enantiomers and epimers and their pharmaceutically acceptable acid addition salts, e.g. 5-[2-(2-naphthylmethyl)-5-benzofuranylmethyl]-2,4- thiazolidinedione. The compd. is obtd. by allowing a compd. of formula IV to react with 5-bromosalicylaldehyde, converting the resultant compd. of formula V into a compd. of formula VI by successive treatment with triethylsilane and with cuprous cyanamide, allowing the compd. of formula VI to react with aluminum/nickel amalgam in the presence of an acid, allowing the resultant compd. of formula VII to react with 2,4-thiazolidinedione and carrying out hydrogenation if necessary. 
     COPYRIGHT: (C)1994,JPO
Sealants to arrest microcavitated caries. 75 microcavitated ICDAS 3 lesions will be sealed by the use of Glass ionomer sealant, EQUIA (GC) in first permanent molars.
A canola protein isolate having a protein content of at least about 90 wt % (N×6.25), preferably at least about 100 wt %, and consisting predominantly of the 2S protein and substantially free from the 7S and 12S proteins is prepared. In one aspect, canola oil seed meal is extracted with aqueous protein solution at an elevated temperature to preferentially extract 2S protein from the meal to produce a canola protein solution containing predominantly 2S protein. The 2S canola protein is recovered as an isolate. In another aspect, the canola oil seed meal is extracted with aqueous saline solution to extract 2S, 7S and 12S proteins from the meal. The aqueous protein extract solution is heat treated at an elevated temperature to precipitate 7S and 12S proteins and leave a 2S protein solution from which the isolate may be recovered. In a further aspect, the aqueous protein solution is concentrated prior to the heat treatment.
In this study, the coordinator investigator proposes to build a platform for perfusing in normothermic conditions all grafts with histologically proven macrosteatosis ≥ 30% that will be considered as unsuitable for upfront LT. These grafts have to be alloacted to one of the 3 liver transplantation centers of Assistance Publique des Hôpitaux de Paris. Eligible grafts (macrosteatosis ≥ 30%, no severe fibrosis or cirrhosis) will be shipped to the platform for normothermic perfusion. Perfusion will be started provided that cold ischemia time do not exceed 8 hours. Parameters of grafts viability (lactates, bile production, flow) will be monitored. After a minimum of 4 hours of normothermic perfusion (not exceeding 16 hours), grafts fulfilling strict criteria (homogeneous aspect of the liver without any necrotic regions, lactates \< 2.5 mmol/l and continuous production of bile with at least one of the following criteria: pH of perfusate \> 7.3, arterial flow \> 150 ml/min and portal flow \> 500 ml/min, homogeneous perfusion of the graft) will be considered suitable for transplantation. Recipient will be transferred to the operating room, and first phase of LT (i.e, laparotomy and total hepatectomy) will be started. Simultaneously, grafts will be shipped to the center of initial allocation. Perfusion will be pursued during the transport from the platform to the recipient. Recipients (≥18 years and ≤ 70 years) have to be enlisted for LT with an estimated waiting time \> 6 months (i.e., MELD score \< 25) and who signed an informed consent.